June 11, 2020 / 5:27 AM / a month ago

BRIEF-U.S. FDA Approves Novartis’ Updated Beovu Label - Statement

June 11 (Reuters) - Novartis AG:

* US FDA APPROVES UPDATED NOVARTIS BEOVU® LABEL, TO INCLUDE ADDITIONAL SAFETY INFORMATION

* NOVARTIS IS CONFIDENT THAT BEOVU CONTINUES TO REPRESENT AN IMPORTANT TREATMENT OPTION FOR PATIENTS WITH WET AMD, WITH AN OVERALL FAVORABLE BENEFIT/RISK PROFILE

* UPDATE TO US LABEL INCLUDES ADDITION OF SUB-SECTION DEDICATED TO RETINAL VASCULITIS AND/OR RETINAL VASCULAR OCCLUSION Source text: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below